Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma

Osnat Bairey, Dorit Blickstein, Pinhas Stark, Miron Prokocimer, Hila Magen Nativ, Ilia Kirgner, Mati Shaklai

Research output: Contribution to journalArticlepeer-review


Cancer antigen 125 (CA 125) is a glycoprotein expressed in normal tissues originally derived from coelomic epithelia such as peritoneum, pleura, pericardium, fallopian tubes and endometrium. Serum CA 125 levels are elevated in various benign and malignant conditions that involve stimulation of these tissues. Although elevated levels have been reported in patients with non-Hodgkin's lymphoma (NHL), its role as a prognostic factor remained uncertain. In this study, serum CA 125 levels were measured prospectively in 108 consecutive patients with NHL: at diagnosis in 106, in remission in 39 and at relapse in 7. Levels were elevated in 43% at diagnosis. This finding was associated with advanced disease stage, bulky tumors, bone marrow involvement, extranodal disease (in stages III and IV), occurrence of B symptoms, pleural or peritoneal effusions, high serum LDH levels, high serum β2 microglobulin (β2-M) levels, elevated International Prognostic Score, poor performance status and partial or no response to treatment. No difference in CA 125 level was found between the indolent and aggressive lymphomas. Serum CA 125 levels at diagnosis had strong association with event-free and overall survival (p = 0.01 and 0.003, respectively), with the patients with increased levels having worse survival. Patients with high CA 125 levels at diagnosis who achieved remission showed a significant decrease in CA 125 levels in remission. In conclusion, CA 125 is not only a reliable marker for staging and assessing tumor activity in NHL, elevated levels are also predictive of decreased survival.

Original languageEnglish
Pages (from-to)1733-1738
Number of pages6
JournalLeukemia and Lymphoma
Issue number10
StatePublished - 1 Oct 2003


  • CA 125
  • Non-Hodgkin's lymphoma
  • Prognosis
  • Survival


Dive into the research topics of 'Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this